Your session is about to expire
← Back to Search
Semaglutide 2.4 mg for Obesity (STEP 10 Trial)
STEP 10 Trial Summary
This trial is studying whether semaglutide can help people with obesity and prediabetes lose weight and improve their blood sugar.
- Obesity
STEP 10 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSTEP 10 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 3 trial • 1210 Patients • NCT03552757STEP 10 Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there still positions open for this clinical research?
"According to the latest information from clinicaltrials.gov, this particular trial is not currently seeking patients. The trial was first posted on September 6th, 2021 and was last updated on March 22nd, 2022. Although this study is not presently looking for volunteers, there are 1193 other trials that are."
What purpose does this clinical trial serve?
"The primary outcome variable that the study's sponsor, Novo Nordisk A/S, is measuring is change in body weight over the course of the 52 weeks of the study. Additionally, this research is looking at secondary outcome measures like change in glycated haemoglobin (HbA1c), triglycerides, and total cholesterol, all of which will be measured as percentages."
What are the risks associated with Semaglutide 2.4 mg treatments?
"Semaglutide 2.4 mg is in Phase 3 of clinical trials, meaning that there is both efficacy data and multiple rounds of safety data supporting its use."
Is this a new approach to this particular disease?
"Semaglutide 2.4 mg was first studied in 2018 by Novo Nordisk A/S. After the positive results of the initial study involving 1387 patients, Semaglutide 2.4 mg was approved for Phase 4 drug trials. Currently, there are 59 active trials in 55 countries and 711 cities."
Is Semaglutide 2.4 mg a common medication that has been tested in other clinical trials?
"Semaglutide 2.4 mg is being trialed in 59 active studies, 27 of which are in Phase 3. Most investigations for Semaglutide 2.4 mg are based in Loma Linda, although there are 3696 total clinical trial locations for Semaglutide 2.4 mg."
Share this study with friends
Copy Link
Messenger